• Explore /
  • Poster
  • / A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.

A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.

Abstract Poster

Authors

null

Huiping Li

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Huiping Li , Jiayang Zhang , Rutie Yin , Nan Song , Youzhong Zhang , Yu Zhang , Keqiang Zhang , Hongming Pan , Ke Wang , Ge Lou , Li Guiling , Ben Zhang , Quanren Wang , Yunong Gao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

NCT03075462

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5539)

DOI

10.1200/JCO.2022.40.16_suppl.5539

Abstract #

5539

Poster Bd #

418

Abstract Disclosures

Similar Posters

First Author: Junning Cao

First Author: Shalu Pahuja

First Author: Taofeek Kunle Owonikoko

First Author: Jung-min Lee